Efficacy of duloxetine in addition to self-management strategies for treatment of chronic paiful temporomandibular disorder: a randomized, placebo-controlled clinical trial

• Ano de defesa: 2021
• Autor(a) principal: Costa, Dyna Mara Ferreira
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: eng
• Instituição de defesa: Biblioteca Digitais de Teses e Dissertações da USP
• Palavras-chave em Português: Autocuidado; Chronic pain; Cloridrato de duloxetina; Dor crônica; Duloxetine hydrochloride; Ensaio clínico controlado aleatório; Limiar de dor; Pain threshold; Randomized controlled trial; Self-care; Síndrome da disfunção da articulação temporomandibular; Temporomandibular joint dysfunction syndrome
• Link de acesso: https://www.teses.usp.br/teses/disponiveis/25/25146/tde-06122021-111809/

Rigorous evidence for combining different therapies for chronic painful temporomandibular disorder (TMD) is limited. Therefore, we conducted a randomized, double-blind, placebocontrolled trial 1) to assess the efficacy of duloxetine in addition to self-management (SM) strategies for treatment of chronic TMD; 2) to investigate whether baseline conditioned pain modulation (CPM) predicts the efficacy of duloxetine in TMD individuals; and 3) to conduct an exploratory analysis of five phenotyping domains pain, psychological, sleep, quantitative sensory testing and CPM to examine predictors of response to SM-duloxetine. Participants were randomized 1:1 to duloxetine 60 mg or placebo once daily for 12 weeks. Moreover, all participants were treated with a SM program. The primary outcomes were a) the change in the pain intensity from baseline to week 12 and b) CPM-sequential paradigm at baseline. Supplemental pain measures, physical and emotional functioning outcomes were also evaluated. Modified baseline observation carried forward, ANCOVA, multiple linear regression and relative risk were applied to the data (p<0.050). Eighty participants were randomized and 78 were included in the intention-to-treat analysis. Pain intensity decreased significantly over time with participants on SM-duloxetine and SM-placebo, reporting reductions from baseline of 30% and 36%, respectively, but did not differ significantly between groups (0.3, 95% CI: -1.1, 1.7; p = 0.82). A more efficient CPM was associated with a greater pain intensity reduction (p=0.035) after 12 weeks of treatment, regardless the treatment group. Furthermore, phenotypes, e.g., severe pain intensity, pain disability, painful comorbidity and anxiety symptoms were indicative of the likelihood of response to SM-duloxetine. In conclusion, there is no beneficial effect of adding duloxetine to SM strategies for treatment of chronic TMD, although high attrition and confidence interval interpretation preclude firm conclusions. Moreover, this randomized clinical trial demonstrated the feasibility of applying patient phenotyping assessment to predict short-term treatment response in chronic TMD individuals, which can contribute to the development of mechanism-based treatments of orofacial pain.